Pharmacokinetics: HIV Drugs

Slides:



Advertisements
Similar presentations
Egyptian Guidelines For Management of Chronic Hepatitis B
Advertisements

IAS–USA Managing Antiretroviral Failure in 2012 Jennifer Hoy, MD Professor of Medicine Director, HIV Medicine The Alfred Hospital FINAL: Presented.
Summary of ARV prescribing guidelines in London These slides summarise the recommendations by the London HIV Consortium for prescribing antiretrovirals.
Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Prabhdeep Sidhu Candidate PharmD 2015 Western University of Health Sciences Mar 28, 2014.
1 First Clinic Visit for Patients with HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Nurses SOAR! Training Curricula Series For More Information and Inquiries:
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
New Treatment Paradigms for Therapeutically-Naïve and Treatment-Experienced HIV Patients A Customized CME Learning Experience.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
HIV Principles in Primary Care and Triage of the HIV patient David Aymond, MD, AAHIVM.
Update on HIV Therapy Elly T Katabira, FRCP Department of Medicine Makerere University Medical School Scaling up Treatment Programs: Issues, Challenges.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,
ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell.
Michael Hughes, MD Assistant Clinical Professor UCR Eisenhower Medical Associates.
Taking a Sexual History Katherine Marx, MS, MPH, FNP-BC.
HIV: WHAT IS NEW? DR NYA EBAMA, M.D. LOWCOUNTRY INFECTIOUS DISEASES, PA CARETEAM PLUS, INC SEPTEMBER 18, 2015.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
MSUCOM OST574 HIV And OB/GYN Peter G. Gulick, DO, FACP, FACOI, FIDSA Associate Professor College of Osteopathic Medicine Michigan State University 1.
Hepatitis B virus infection in renal transplant recipients
Treatment of HBV/HCV Coinfection
Phase 3 Treatment-Naïve and Treatment-Experienced
HIV Part Dos By Alaina Darby.
Treatment-Naïve Adults
Learning objectives Define HIV treatment goals
Antiretroviral Therapy (ART)
PrEP for HIV Prevention
HIV Tutoring By Alaina Darby.
TREATMENT OF HIV.
Preexposure Prophylaxis (PreP) for the Prevention of HIV
undetectable (undetectable-6.25)
Pharmacokinetics: psychotropic drugs
A protocol in development IMPAACT Prevention Scientific Committee
Pharmacokinetics: HIV Drugs
PrEP as an HIV Prevention Tool in Queer Communities of Color: Barriers and Opportunities BACKGROUND Joanne Stekler, MD MPH.
ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:
POST EXPOSURE PROPHYLAXIS IN HCW
What’s New in the Perinatal Guidelines
Short Summary German-Austrian ART Guidelines 2017
Pharmacokinetics: immunosuppressive drugs
Treating Hep C with Novel Agents
Switch to DTG + 3TC ASPIRE Study.
Section 22.4 Protecting Yourself From HIV and AIDS Objectives
Pre-Exposure Prophylaxis (PrEP) for HIV Infection
Human Immunodeficiency Virus (HIV)
PrEP Pre-Exposure Prophylaxis
Section 22.4 Protecting Yourself From HIV and AIDS Objectives
Next Generation Capsid Inhibitor: GS–CA1
Just when you thought you knew everything.
100 Partners PrEP[5] Efficacy 75% Adherence 81% 80
Switch to DRV/r monotherapy
Comparison of INSTI vs EFV
HIV.
Diagnosis and Management of HIV-2 in Adults
Farinaz khan Dept of FCM
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
5th edition NTP MANUAL OF PROCEDURES Case Finding
Sequencing cohorts Open-label Design W8 W12 ≥ 18 years
U=U Guidance for Implementation in Clinical Settings
ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE
Undetectable = Untransmittable
Bob Holtkamp, Director of Prevention & Outreach
INTRODUCTION OBJECTIVES METHODS RESULTS DISCUSSION
Presentation transcript:

Pharmacokinetics: HIV Drugs Allie Punke (apunke@uthsc.edu)

Renal function Patients with HIV are at an increased risk of having nephropathy that can lead to ESRD DJ is a Caucasian female who was just diagnosed with HIV. When/should you recommend for her to be screened for renal function? What are you specifically screening for when performing renal function tests?

Renal function CG is a HIV+ (diagnosed about a year ago) African American male. At your appointment with him today, he tells you he sometimes forgets to take his medications for HIV. The CD4 and HIV RNA count today is 150 and 900, respectively. His renal function was stable when he was diagnosed with HIV. Should we check his renal function today?

Renal function When to screen patients for renal function: Screen ALL patients when they are diagnosed with HIV Yearly screening if patients are at high risk African American CD4<200 HIV RNA>400 Family history of renal problems

Hepatic function What makes HIV + patients at increased risk for liver function abnormalities? 1. Patients may be co-infected with HBV or HCV (If co-infected, patients have increased risk of drug induced liver injury) 3. Medications (Nevirapine/TB drugs)

Hepatic function GP is a 28 YO AA male who was just diagnosed with HIV. How often should we monitor his hepatic function? ALT/AST Q 6-12 months.

Dose adjustments Patients with renal or hepatic issues will most likely: Not be able to take medications that are _________. Will often require _________ doses Will be advised to take medications _________ HD session. Will or will not require trough concentrations.

Dose adjustments Generally speaking…. Dose adjustments (hepatic/renal) should be made for the following drugs: 1. INST 2. NNRTI INST (integrase inhibitors): dose adjustments not commonly needed for INST’s. NNRTI; renal adjustment less common, adjustments not needed with mild impairment (most have no dosage recommendation/no recommendation for child pugh C) PI: hepatic dose common, renal adjustment is less common NRTI: most need renal adjustment

Dose adjustments 3. PI 4. NRTI

Dose adjustments AB is a 45 YO African American HIV + male. His renal function has been gradually declining, and now he is requiring dialysis on M, W, F. His medications include: efavirenz, maraviroc, enfuvirtide, tenofovir, atorvastatin, amlodipine. Which medication only needs to be given once a week? When should the other HIV medications be dosed?

Dose adjustments In general, patients with renal/hepatic issues should avoid co-formulated products; however, there is one combination medication which has lower renal cut-off that patients may be on until renal dysfunction becomes worse: Truvada (combo of emtricitabine and tenofovir both have same cut off for renal function)

Dose adjustments T/F: Emtricitabine is a member of the NNRTI class, which generally does not require renal dose adjustment. T/F: Atripla does not require dose adjustment for patients with decreased renal function. T/F: Stribild can be recommended without testing renal function when initiating, but yearly renal function screening is recommended. False (NRTI, requires renal adjustment) False (has tenofovir and emtricitabine in it, which do) False (has tenofovir/emtricitabine in it) not rec <70. D/C if <50

Drug monitoring T/F: Most patients with HIV receiving antiretroviral medication should have their medications monitored through the use of drug concentrations T/F: Patients who do have their HIV medications monitored experience quicker time to undetectable RNA load and less side effects T/F: Monitoring HIV medications is recommended in HIV guidelines due to clinical trials showing that monitoring improves clinical outcomes False. NOT the standard of care.

Dose adjustments A patient who was recently diagnosed with HIV has been on anti-retroviral therapy for the past 3 months. She reports being extremely adherent (the pill counts also show she has been adherent). However, her CD4 count is still very low and her RNA is quite high. What can we consider doing? 1. DDI 2. Change in physiologic state 3 Pregnancy 4. Pretreated patient experiencing virologic failure Use of alternative dosing regimens Lack of expected virologic response in adherence individuals

Pre-exposure prophylaxis A 23 YO Caucasian female with history of IV drug abuse asks if there’s any medication to reduce her chances of acquiring HIV. What medication would you want to tell her about? If you give her the medication, when would you want to schedule a follow up visit? Truvada (TDF/FTC 300/200) AT LEAST Q3 months

Pre-exposure prophylaxis What are some things to monitor for a patient receiving pre-exposure prophylaxis? If a patient becomes HIV + while on prophylaxis (and the diagnosis is confirmed and CD4 count is ordered), what should we do?

Pre-exposure prophylaxis For all groups (MSM, heterosexuals, IVDU)…what must we make sure they do NOT have before initiating HIV pre-exposure prophylaxis? Documented neg HIV test, no signs/symptoms of HIV infection, normal RF/no CI meds, documented hep B virus and vacc status

Pre-exposure prophylaxis Should we initiate it in these patients? 1. Gay male who was diagnosed with gonorrhea 5 months ago. 2. IV drug abuser who sometimes shares needles with her friend who was just diagnosed with HIV 3. Heterosexual male who thinks he may be having symptoms of HIV after a previous partner informed him that she is HIV+

Pre-exposure prophylaxis

summary Recognize the need to monitor for renal and hepatic function in HIV + patients Recognize the classes of medications as well as the combination products that generally need to be adjusted for renal or hepatic function Know the drug used for pre-exposure prophylaxis Know which patients are eligible for pre-exposure prophylaxis

Questions about this or previous session? Good luck!